Compare Outcome of Enhanced Recovery After Cesarean Surgery and Conventional Care

August 25, 2020 updated by: Rajavithi Hospital

Compare Outcome of Enhanced Recovery After Cesarean Surgery and Conventional Care in Rajavithi Hospital

Research objective to compare outcome(Length of stay, pain score, opioid drug use, Bowel function and complication ) of ERAS protocol and conventional care in pregnant women after elective cesarean section in Rajavithi hospital.

Study Overview

Detailed Description

Research design is Randomized control trial. The pregnant women who go to elective cesarean section don't know the allocation. The group of ERAS protocol was separated from Conventional care in patient care unit.

The Pregnant are randomly in two group. In the ERAS group the pregnant receive the the intervention for preoperative care(Counselin, H2- antagonist and metroclopramide for prevent aspiration, Drink clear liquid until 2 hour before surgery), Intraoperative care (first generation cephalosporin in 60 minute before surgery, Clorhexidine for skin cleansing and Povidine for vaginal cleansing, regional anesthesia, keep warming, blunt expansion of uterine incision, do not peritoneal suture and subcuticular suture if less than 2 cm, local wound anesthesia.), post operative care ( Paracetamol and NSAIDs for for pain control, early remove catheter and ambulation, 5-HT3 antagonist for prevent nausea)

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bangkok, Thailand, 10400
        • Rajavithi Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Pregnant women who scheduled for elective Cesarean section at Rajavithi Hospital

Exclusion Criteria:

  • Pregnant women who has preeclampsia with severe feature
  • Pregnant women who has diabetes mellitus with uncontrolled blood sugar
  • Pregnant women who has blood loss > 1,500 ml after surgery
  • Pregnant women who has chrioamnionitis.
  • Pregnant women who has severe medical disease
  • Pregnant women who has BMI >= 40 kg/m2
  • Pregnant women who has placenta adherence.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Conventional care
This group is conventional care of pregnant women after Cesarean section
EXPERIMENTAL: ERAS protocol
This protocol for improve outcome of pregnant women after Cesarean section
  • Counseling
  • H2- antagonist and metroclopramide for prevent aspiration
  • Drink clear liquid until 2 hour before surgery
  • First generation cephalosporin in 60 minute before surgery
  • Clorhexidine for skin cleansing and Povidine for vaginal cleansing
  • Regional anesthesia
  • Keep warming
  • Blunt expansion of uterine incision
  • Do not peritoneal suture and subcuticular suture if less than 2 cm
  • Local wound anesthesia.
  • Paracetamol and NSAIDs for for pain control
  • Early remove catheter and ambulation
  • 5-HT3 antagonist for prevent nausea

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Compare length of stay of pregnant women after Cesarean section between ERAS protocol and conventional care
Time Frame: 1 year
The primary outcome is length of stay (Day)
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Compare pain of pregnant women after Cesarean section between ERAS protocol and conventional care
Time Frame: 1 year
The outcome is pain score (visual analogue scale )
1 year
Compare opioid use of pregnant women after Cesarean section between ERAS protocol and conventional care
Time Frame: 1 year
The outcome are opioid use (Meperidine, Tramadol, Morphine)
1 year
Compare complication of pregnant women after Cesarean section between ERAS protocol and conventional care
Time Frame: 1 year
The outcome are complication after surgery such as fever, wound infection, wound dehiscence, metritis
1 year
Compare bowel function of pregnant women after Cesarean section between ERAS protocol and conventional care
Time Frame: 1 year
The outcome is time to passing gas after surgery(hour)
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 15, 2020

Primary Completion (ACTUAL)

July 30, 2020

Study Completion (ACTUAL)

July 30, 2020

Study Registration Dates

First Submitted

August 25, 2020

First Submitted That Met QC Criteria

August 25, 2020

First Posted (ACTUAL)

August 28, 2020

Study Record Updates

Last Update Posted (ACTUAL)

August 28, 2020

Last Update Submitted That Met QC Criteria

August 25, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 103/2562

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on ERAS

3
Subscribe